A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

Since the US Food and Drug Administration (FDA) implemented a ban on ‘compounded’ versions of Wegovy on 22 May, new ...

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO -2.49%) were lower by 4% as of 11 a.m. ET today. The move comes as the fallout from the sudden termination of its partnership with ...

(Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome ...

HYDERABAD, June 24 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO) on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli Lilly (LLY.N) began marketing ...

The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to the loss of lean mass. Price Action: NVO stock is up 0.04% at $79.36 at the last check Wednesday.